UnitedHealth Group is an undervalued stock with some promising long-term growth prospects. Johnson & Johnson's business is leaner without its consumer health segment, and it has been focusing more ...

Investing in the stock market isn't without the risks, but what if you could generate extra income from your investment? If you are a risk-averse investor like me and want to build a retirement por...

The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.

Eli Lilly (LLY) is up over 80% year-over-year. Lee Brown discusses health care stocks.

J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.

Johnson & Johnson reported strong earnings growth last year but its shares only offer a 3% dividend yield at recent prices. Verizon offers a big 6.3% dividend yield at recent prices but its bottom ...

One of the best ways to create wealth is finding the right dividend stocks to buy and hold. No other asset class has performed as well as buying equities, not gold, not bonds, not real estate.

Johnson & Johnson reported strong Q4 FY23 results and reaffirmed guidance for FY24, exceeding expectations. The company's pharmaceutical business has the potential for 5-7% long-term growth, driven...

OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over ...

Six months after parting ways with its consumer health unit, Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding...

The commercial success of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato for use in treatment-resistant depression and major depressive disorder with suicidal ideation bodes well fo...

Joseph Wolk, Johnson & Johnson Chief Financial Officer, says the drug pipeline is well positioned for this year. He also comments on their earnings and the use of artificial intelligence in medicin...

The settlement does not resolve the tens of thousands of lawsuits alleging that J&J's talc-based products caused cancer.

Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript

Johnson & Johnson edged out estimates and delivered in-line guidance for 2024. Concerns about legal settlements and competition for drug Stelara seemed to weigh on the stock.